The societal burden of osteoporosis in Sweden

Bone

Volumn 40, Issue 6, 2007, Pages 1602-1609

  Borgström, Fredrik ^a,b   Sobocki, Patrik ^a,b   Ström, Oskar ^a   Jönsson, Bengt ^c  

^a European Health Economics   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Burden; Costs; Fractures; Osteoporosis; QALYs

Indexed keywords

ADULT; AGED; ARTICLE; COMMUNITY CARE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; FRACTURE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PREVALENCE; PUBLIC HEALTH PROBLEM; QUALITY ADJUSTED LIFE YEAR; RISK; SWEDEN;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COST OF ILLNESS; COSTS AND COST ANALYSIS; FEMALE; FOREARM INJURIES; FRACTURES, BONE; HEALTH CARE COSTS; HIP FRACTURES; HOSPITAL COSTS; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; OSTEOPOROSIS; QUALITY-ADJUSTED LIFE YEARS; SPINAL FRACTURES; SWEDEN;

EID: 34248654854     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.02.027     Document Type: Article

References (51)

1. Elffors I., Allander E., Kanis J.A., Gullberg B., Johnell O., Dequeker J., et al. The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos. Int. 4 5 (1994) 253-263
2. National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoporos. Int. 8 Suppl. 4 (1998) 1-88
3. Kanis J.A., Johnell O., Oden A., Borgstrom F., Zethraeus N., De Laet C., et al. The risk and burden of vertebral fractures in Sweden. Osteoporos. Int. 15 1 (2004) 20-26
4. Cooper C., Campion G., and Melton III L.J. Hip fractures in the elderly: a world-wide projection. Osteoporos. Int. 2 6 (1992) 285-289
5. Osteoporos-prevention, diagnostik och behandling, in SBU rapport Nr 165, S.-S.b.f.m. utvärdering, Editor. 2003: Stockholm.
6. Drummond M., O'Brien B., Stoddart G., and Torrance G. Methods for the economic evaluation of health care programmes (1997), Oxford Univ. Press, Oxford
7. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J. Health Econ. 16 1 (1997) 33-64
8. Statistics Sweden. Sweden's statistical databases, http://www.scb.se/eng/databaser/ssdasp. Available from: http://www.scb.se.
9. Borgstrom F., Zethraeus N., Johnell O., Lidgren L., Ponzer S., Svensson O., et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos. Int. (2005) 1-14
10. Zethraeus N., and Gerdtham U.G. Estimating the costs of hip fracture and potential savings. Int. J. Technol. Assess. Health Care 14 2 (1998) 255-267
11. Zethraeus N., Stromberg L., Jonsson B., Svensson O., and Ohlen G. The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop. Scand. 68 1 (1997) 13-17
12. Swedish National Inpatient Register and Causes of Death Register, The Swedish National Board of Health Centre - The Epidemiological Centre.
13. Kanis J.A., Johnell O., Oden A., Sembo I., Redlund-Johnell I., Dawson A., et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos. Int. 11 8 (2000) 669-674
14. Cauley J.A., Thompson D.E., Ensrud K.C., Scott J.C., and Black D. Risk of mortality following clinical fractures. Osteoporos. Int. 11 7 (2000) 556-561
15. Center J.R., Nguyen T.V., Schneider D., Sambrook P.N., and Eisman J.A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353 9156 (1999) 878-882
16. Cooper C., Atkinson E.J., Jacobsen S.J., O'Fallon W.M., and Melton III L.J. Population-based study of survival after osteoporotic fractures. Am. J. Epidemiol. 137 9 (1993) 1001-1005
17. Jalava T., Sarna S., Pylkkanen L., Mawer B., Kanis J.A., Selby P., et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J. Bone Miner. Res. 18 7 (2003) 1254-1260
18. Kanis J.A., Oden A., Johnell O., De Laet C., and Jonsson B. Excess mortality after hospitalisation for vertebral fracture. Osteoporos. Int. 15 2 (2004) 108-112
19. Oden A., Dawson A., Dere W., Johnell O., Jonsson B., and Kanis J.A. Lifetime risk of hip fractures is underestimated. Osteoporos. Int. 8 6 (1998) 599-603
20. Johnell O., Kanis J.A., Oden A., Sernbo I., Redlund-Johnell I., Petterson C., et al. Mortality after osteoporotic fractures. Osteoporos. Int. 15 1 (2004) 38-42
21. Zethraeus N., Ben Sedrine W., Caulin F., Corcaud S., Gathon H.J., Haim M., et al. Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos. Int. 13 11 (2002) 841-857
22. Jonsson B., Christiansen C., Johnell O., Hedbrandt J., and Karlsson G. Cost-effectiveness of fracture prevention in established osteoporosis. Scand. J. Rheumatol., Suppl. 103 (1996) 30-38
23. Stockholms stads budgetavräkning 2003 [online]. 2004-12-20]; Available from: www.stockholm.se/files/71600-71699/file_71645.pdf.
24. Uppsala Akademiska Sjukhus, 2004 [online] 2004-05-14]; Available from: http://www.lul.se/svn/.
25. Johnell O., Jonsson B., Jonsson L., and Black D. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21 5 (2003) 305-314
26. Borgstrom F., and Zethraeus N. Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective. Lakartidningen 100 1-2 (2003) 36-40
27. Borgstrom F., Johnell O., Jonsson B., Zethraeus N., and Sen S.S. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34 6 (2004) 1064-1071
28. Jonsson L., Borgstrom F., and Zethraeus N. Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial. Ugeskr. Laeger. 165 43 (2003) 4112-4116
29. Kanis J.A., Borgstrom F., Johnell O., and Jonsson B. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos. Int. 15 11 (2004) 862-871
30. Kanis J.A., Borgstrom F., Johnell O., Oden A., Sykes D., and Jonsson B. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos. Int. 16 1 (2005) 15-25
31. Kanis J.A., Johnell O., Oden A., Borgstrom F., Johansson H., De Laet C., et al. Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos. Int. 16 1 (2005) 6-14
32. Zethraeus N., Borgström F., Ström O., Kanis J.A., and Jonsson B. Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model. Osteoporos. Int. 18 1 (2007) 9-23
33. Borgstrom F., Johnell O., Kanis J.A., Oden A., Sykes D., and Jonsson B. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 22 17 (2004) 1153-1165
34. Ström O., Borgstrom F., Sen S.S., Boonen S., Haentjens P., Johnell O., and Kanis J.A. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos. Int. (2007)
35. Ekman M., Zethraeus N., Dahlstrom U., and Hoglund C. Cost-effectiveness of bisoprolol in chronic heart failure. Lakartidningen 99 7 (2002) 646-650
36. Oleksik A., Lips P., Dawson A., Minshall M.E., Shen W., Cooper C., et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J. Bone Miner. Res. 15 7 (2000) 1384-1392
37. Översyn av samhällsekonomiska metoder och kalkylvärden på transportområdet - ASEK review of cost benefit calculation. Methods and valuations in the transport sector. SIKA Rapp. (2002) 4
38. Ekman M., Zethraeus N., Dahlström U., and Höglund C. Är behandling av hjärtsvikt med betablockerare kostnadseffektiv?. Läkartidningen 99 7 (2002)
39. Eichler H.G., Kong S.X., Gerth W.C., Mavros P., and Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health 7 5 (2004) 518-528
40. Burstrom K., Johannesson M., and Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual. Life Res. 10 7 (2001) 621-635
41. Jönsson B., Arvidsson G., Levin L.-Å., and Rehnberg C. Hälsa, sjukvård och tillväxt (2004), SNS förlag
42. Macroeconomics and Health: investing in health for economic development. Report of the Commission on Macroeconomics and Health, W.C.o.M.a. Health, Editor. 2001: Geneva.
43. Hjalte K., Hjelmgren J., Johansson F., and Persson U. Betalningsviljan för ett kvalitetsjusterat levnadsår - en pilotstudie. IHE e-rapport 2005 vol. 1 (2005), Institutet för hälso och sjukvårdsekonomi
44. Henriksson F., Fredrikson S., Masterman T., and Jonsson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur. J. Neurol. 8 1 (2001) 27-35
45. Henriksson F., Agardh C.D., Berne C., Bolinder J., Lonnqvist F., Stenstrom P., et al. Direct medical costs for patients with type 2 diabetes in Sweden. J. Intern. Med. 248 5 (2000) 387-396
46. Kanis J.A., Oden A., Johnell O., Jonsson B., de Laet C., and Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos. Int. 12 5 (2001) 417-427
47. Kanis J.A., Johnell O., Oden A., De Laet C., Oglesby A., and Jonsson B. Intervention thresholds for osteoporosis. Bone 31 1 (2002) 26-31
48. Gullberg B., Duppe H., Nilsson B., Redlund-Johnell I., Sernbo I., Obrant K., et al. Incidence of hip fractures in Malmo, Sweden (1950-1991). Bone 14 Suppl. 1 (1993) S23-S29
49. Rogmark C., Sernbo I., Johnell O., and Nilsson J.A. Incidence of hip fractures in Malmo, Sweden, 1992-1995. A trend-break. Acta Orthop. Scand. 70 1 (1999) 19-22
50. Nilsson R., Lofman O., Berglund K., Larsson L., and Toss G. Increased hip-fracture incidence in the county of Ostergotland, Sweden, 1940-1986, with forecasts up to the year 2000: an epidemiological study. Int. J. Epidemiol. 20 4 (1991) 1018-1024
51. De Laet C.E., van Hout B.A., Burger H., Weel A.E., Hofman A., and Pols H.A. Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos. Int. 10 1 (1999) 66-72